Oncoteq AG - oncology drug development powered by AI

Oncoteq is a clinical stage oncology biotech focused on drug development powered by AI.

Headquartered in Cham, Switzerland, with a focus on innovative treatments for cancer, the company pipeline currently comprises three assets of first-in-class or best-in-class innovative therapeutic options in areas of high unmet need.

What we do

Oncoteq is a clinical stage biotechnology company focused on drug development within oncology.

Oncoteq leverages artificial intelligence to identify the optimal applications of a given molecule and de-risk clinical development.

 

Oncoteq est.
2022
Privately held

10+ Employees

Strategic partners
Innoplexus

Office in Cham

Founded, seeded by Cureteq AG

Latest news

23 September 2024

See you 25-26 Sep in Basel for 24th SACHS Biotech conference

For meetings with CBO, Sarah Holland and CEO, Mads Dalsgaard, please reach out via the partnering system or directly by email/phone.

01 August 2024

Oncoteq proud to sponsor Tiffany’s Pink Pedal Ride, for Breast Cancer research

It was a great honor for Oncoteq to sponsor Tiffany’s Pink Pedal Ride, to raise money for the Tiffany Lynn O’Donnell Foundation. The charity event and the funds raised will support Breast Cancer …

05 January 2024

Meeting at J.P. Morgan 2024?

Looking for partnering or investment with Oncoteq? CEO Mads Dalsgaard, CFO Swati Mehta, and CBO Sarah Holland will be attending so please reach out to set up meeting in San Francisco

Shortcuts

About Us

Oncoteq is a clinical stage biotech, that leverages AI to unlock the value of exciting oncology assets

Pipeline

The Oncoteq pipeline currently comprises three assets focusing on oncology. Oncoteq

Platform

The Cureteq platform uniquely combines a fully flexible and agile biotech company-builder model with AI supported drug development

Transforming drug development

We aim to transform drug development and drive assets beyond value inflection points by:

  • Unlocking hidden value of unattended molecules through AI
  • Combining agility and expertise in a lean structure
  • Flexibly partnering and financing assets